Wednesday, January 16, 2019 12:03:58 PM
One giant pharma stock that I have been following lately is Johnson and Johnson (NYSE:JNJ). Last month, the stock plunged lower after news was reported that the company could still have issues regarding its popular baby powder product. On December 13, 2018, the shares traded as high as $148.58 a share. On December 24, 2018 the shares traded as low as $121.00 before finding a near term bottom with the major stock market indexes. Today, JNJ stock is trading at $128.42 a share. So while the shares have certainly bounced higher they have not come close to their December 13th high. In fact, the stock is signaling weak relative strength at this time. Traders should note that the stock is still trading below its important 200-day moving average, this is actually a sign of weakness. Should the stock break below the key $121.00 support level it would trigger another sell signal in the stock. The next major support level for JNJ stock would be around the $113.00 area. Right now, JNJ is hanging in there, but this is a stock that I will be watching closely.
Nick Santiago
InTheMoneyStocks
Recent JNJ News
- Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More • IH Market News • 09/23/2024 10:32:25 AM
- Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt • Business Wire • 09/20/2024 10:53:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:19:26 PM
- Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims • Business Wire • 09/20/2024 07:43:00 PM
- RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer • PR Newswire (US) • 09/19/2024 10:54:00 PM
- Microsoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with Amazon • IH Market News • 09/17/2024 10:40:35 AM
- Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer • PR Newswire (US) • 09/16/2024 06:50:00 AM
- New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 09/15/2024 06:30:00 AM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer • PR Newswire (US) • 09/14/2024 01:45:00 PM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer • PR Newswire (US) • 09/14/2024 07:10:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:44:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:43:45 PM
- TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease • PR Newswire (US) • 09/11/2024 10:22:00 PM
- Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) • PR Newswire (US) • 09/10/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 08:26:10 PM
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer • PR Newswire (US) • 09/08/2024 05:47:00 PM
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results • Business Wire • 09/05/2024 08:30:00 PM
- Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing • IH Market News • 09/05/2024 10:11:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:48:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 07:51:09 PM
- Form N-PX - Annual Report of proxy voting record of management investment companies • Edgar (US Regulatory) • 08/29/2024 06:05:30 PM
- Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis • PR Newswire (US) • 08/29/2024 12:00:00 PM
- Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress • PR Newswire (US) • 08/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:26:20 PM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM